Every material Form 8-K Immunovant, Inc. has filed with the SEC since February 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Immunovant reported that IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 in Period 2 of a potentially registrational trial in difficult-to-treat rheumatoid arthritis, with FDA discussions planned later this year on the path forward. The company also said it is unlikely to advance IMVT-1402 further in Sjogren's disease beyond the ongoing Phase 2 trial, while its net loss narrowed and cash declined over the period.
IMVT-1402 600 mg ACR20 response at Week 28 was 92.5% vs. 75.6% for placebo (p=0.0139); the 300 mg arm did not differ from placebo.
FDA discussions are planned for later this year on the registrational program in difficult-to-treat rheumatoid arthritis.
Net loss for the quarter ended September 30, 2026 was $97.2 million ($0.47 per share), vs. $126.5 million ($0.73 per share) a year earlier; cash and equivalents were $722.3 million, down from $902.1 million at March 31, 2026.
Immunovant reported a fiscal first-quarter net loss of $153.2 million, or $0.75 per share, for the quarter ended June 30, 2026, up from $120.6 million, or $0.71 per share, a year earlier. The company reported no revenue in the filing, and its cash and cash equivalents fell to $797.8 million from $902.1 million at March 31, 2026, which it says provides runway to the potential commercial launch of IMVT-1402 in Graves' disease.
Net loss was $153.2 million ($0.75 per share) versus $120.6 million ($0.71 per share) a year earlier.
Research and development expenses rose to $142.6 million from $101.2 million, mainly from IMVT-1402 clinical trial activity, including contract manufacturing costs.
General and administrative expenses fell to $17.7 million from $26.0 million.
Cash and cash equivalents were $797.8 million as of June 30, 2026, compared with $902.1 million as of March 31, 2026.
Immunovant reported results for the fourth quarter and fiscal year ended March 31, 2026, with its net loss widening as research and development spending rose to $142.3 million in the quarter, including $39.0 million in contractual costs tied to discontinuing batoclimab after two Phase 3 thyroid eye disease studies missed their primary endpoint. The company also shared preliminary open-label Week 16 data for IMVT-1402 in difficult-to-treat rheumatoid arthritis and said its $902.1 million in cash provides runway to a potential Graves' disease launch. For shareholders, the trial data are a positive step, but losses and spending increased, and the results remain preliminary.
Net loss for the quarter ended March 31, 2026 was $147.9 million ($0.73 per share), up from $106.4 million ($0.64 per share) a year earlier.
Full-year net loss was $505.6 million ($2.77 per share), compared with $413.8 million ($2.73 per share) in fiscal 2025.
IMVT-1402 showed an observed Week 16 ACR20 response rate of 72.7% in 165 evaluable patients in an open-label period; further updates are expected in the second half of calendar 2026.
Cash and cash equivalents totaled $902.1 million as of March 31, 2026.
Immunovant reported results for the fiscal third quarter ended December 31, 2025, with a net loss of $110.6 million ($0.61 per share), compared with $111.1 million ($0.76 per share) a year earlier. Cash and cash equivalents were $994.5 million at December 31, 2025, following a December 2025 underwritten financing with institutional investors and Roivant that generated approximately $550 million in gross proceeds, which the company says extends its cash runway to the potential launch of IMVT-1402 in Graves' disease.
Q3 net loss was $110.6 million ($0.61 per share), versus $111.1 million ($0.76 per share) in the prior-year quarter.
R&D expenses rose to $98.9 million from $94.5 million, driven by IMVT-1402 trial activities, including contract manufacturing costs.
G&A expenses fell to $15.4 million from $19.8 million, mainly due to lower personnel-related expenses, market research and IT costs.
The December 2025 financing generated approximately $550 million in gross proceeds; shares outstanding were 203,316,885 at December 31, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Immunovant, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →